Carmel-based Heartland Consumer Products says Speedway offers knockoff sweetener in packets that are too similar to Splenda’s packaging, which could confuse customers.
Josh Smiley, Lilly’s CFO since 2018, resigned from the company after the drugmaker said he had engaged in a improper personal relationship with an employee.
If it becomes law, House Bill 1309, authored by Republican Rep. Karen Engleman of Georgetown, will allow employees to request accommodations from their employer—something pregnant workers are already allowed to do.
Joshua Smiley, who was Lilly’s second-highest-paid employee, was named CFO in January 2018. Lilly said Smiley also engaged in “inappropriate personal communications” with other employees.
American Resources Corp. is the latest central Indiana firm to jump on the “blank-check company’ bandwagon—forming a shell company that uses public offering proceeds to scoop up an acquisition target.
Lilly has spent three decades and more than $3 billion trying to find a way to treat Alzheimer’s disease. Its latest drug, donanemab, finally shows real promise.
The team’s return to the IUPUI campus follows challenges in scheduling weekend games at Lucas Oil Stadium, which already has a busy slate of conventions and other sporting events throughout the year—including Indianapolis Colts home games.
Since the pandemic has shifted many of these interactions online, local dealmakers say they feel the loss of assessing non-verbal cues and interactions among members of a management team as they decide whether to acquire companies or invest in startups.
Social media startup Stockteamup has partnered with the philanthropic arm of a hip-hop-inspired snack company to teach financial investing to Black communities.
Senate Bill 385, authored by Republican Sen. Jack Sandlin of Indianapolis, would add two years to a 2019 bill that had called for a new special tax district—known as a professional sports development area—to be established in Marion County by mid-2022.
The maker of animal feeds and vaccines also is closing research and development sites in Germany and New Zealand, and making smaller cuts elsewhere. Altogether, Elanco is chopping 350 jobs in 23 countries.
